Pharmaceutical Product Monograph: Doxepin Hydrochloride Capsules
In the pharmaceutical industry, Doxepin Hydrochloride is a potent Tricyclic Antidepressant (TCA) with significant antihistaminic properties. As a pharmacist and manufacturer, I classify this as a “Multimodal Psychotropic”—it is technically unique because, at different dosages, it functions as an antidepressant, an anti-anxiety agent, and one of the most powerful sleep aids available.
At your WHO-GMP facility in Mumbai, Doxepin is a versatile SKU for Psychiatry, Neurology, and Dermatology portfolios. Its high affinity for $H_1$ receptors makes it a “Problem Solver” for patients with comorbid insomnia and depression.
Therapeutic Profile: Primary Indications
Doxepin is indicated for the treatment of psychoneurotic patients with depression and/or anxiety.
| Indication | Clinical Context | Technical Rationale |
| Major Depressive Disorder | Psychiatry | Especially effective when depression is associated with anxiety and sleep disturbances. |
| Anxiety States | Psychoneurosis | Used in patients with neuroses, organic disease anxiety, or involutional depression. |
| Chronic Insomnia | Sleep Medicine | At very low doses (3 mg – 6 mg), it is used specifically for sleep maintenance (staying asleep). |
| Chronic Urticaria | Dermatology | Occasionally used off-label for severe, treatment-resistant itching due to its massive antihistamine effect. |
Mechanism: Reuptake Inhibition & Receptor Blockade
Doxepin works by increasing the concentration of neurotransmitters while simultaneously blocking specific receptors:
NE & Serotonin Reuptake Inhibition: It technically blocks the reuptake of Norepinephrine and Serotonin at the presynaptic terminals. This “lifts” the mood and reduces anxiety.
$H_1$ Receptor Antagonism: Doxepin has an incredibly high affinity for Histamine $H_1$ receptors (significantly higher than diphenhydramine). This accounts for its powerful sedative and anti-itch effects.
Cholinergic & Adrenergic Blockade: It also has moderate anticholinergic and alpha-1 adrenergic blocking activity, which contributes to its side-effect profile (dry mouth, sedation).
The Pharmacist’s “Technical Warning”
The “Taper” Rule: Doxepin must never be stopped abruptly. Technical withdrawal symptoms (nausea, headache, malaise) can occur. It must be tapered off over several weeks.
The “Anticholinergic” Burden: It can cause “Dryness” (dry mouth, blurred vision, constipation, urinary retention). This is a major concern for elderly patients (Beers Criteria).
Alcohol Interaction: Doxepin significantly potentiates the effects of alcohol. Patients must be warned that one drink may feel like three.
MAOI Gap: It is strictly contraindicated with MAO Inhibitors. A 14-day washout period is technically required when switching between these classes to avoid Serotonin Syndrome.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at Healthy Life Pharma / Healthy Inc:
The “Sleep-Dose” USP: On your digital marketplace, highlight your capability to manufacture Low-Dose Doxepin (3 mg / 6 mg). While the 25 mg – 75 mg capsules are for depression, the low-dose market for “Sleep Maintenance Insomnia” is a high-growth niche in Western B2B markets.
The “Derm-Neuro” Strategy: Position Doxepin as a “Dual-Action Solution” for geriatric dermatology. It treats the chronic itch and the anxiety/insomnia that often accompanies it in elderly patients.
Stability: Doxepin is light-sensitive. For Mumbai-based export, ensure your PVC/PVDC or Alu-Alu blistering is opaque or amber-tinted to prevent photodegradation of the active hydrochloride salt.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Doxepin 10 mg, 25 mg, 50 mg, and 75 mg to support your registration in international mental health tenders.